


Product Data Sheet

Cas No.:	1239358-85-0	Cat. No:	PL04912
Product Name:	Ilginatinib hydrochloride		
Product synonym:	-		
Chemical name:	Ilginatinib hydrochloride		
MF:	C21H21CLFN7	FW:	425.889745473862
Purity:	≥98%	Batch No.:	-
Storage:			
Structural formula:			
λmax:	-	Formulation:	-
Solubility :			
SMILES :	[H]Cl.CN1N=CC(C2=CC(N[C@H](C3=CC=C(F)C=C3)C)=NC(NC4=NC=CN=C4)=C2)=C1		
InChI Code:	-		
InChI Key:			
WARNING This product is not for human or veterinary use.			

Product Description

Ilginatinib hydrochloride (NS-018 hydrochloride) 是一种高度有效的，可口服的 JAK2 抑制剂，IC₅₀ 值为 0.72 nM，对其选择性是对 JAK1 的 46 倍 (IC₅₀, 33 nM)，JAK3 的 54 倍 (IC₅₀, 39 nM)，以及 Tyk2 的 22 倍 (IC₅₀, 22 nM)。

生物活性	Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable JAK2 inhibitor, with an IC ₅₀ of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC ₅₀ , 33 nM), JAK3 (IC ₅₀ , 39 nM), and Tyk2 (IC ₅₀ , 22 nM).
IC50 & Target[1][2]	JAK2 0.72 nM (IC50) Tyk2 22 nM (IC50)
体外研究(In Vitro)	<p>Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active JAK2 inhibitor, with an IC₅₀ of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC₅₀, 33 nM), JAK3 (IC₅₀, 39 nM), and Tyk2 (IC₅₀, 22 nM). Ilginatinib hydrochloride also inhibits Src-family kinases, especially SRC and FYN, and weakly inhibits ABL and FLT3 with 45- and 90-fold selectivity for JAK2, respectively. Ilginatinib hydrochloride shows potent inhibitory activity against cell lines JAK2V617F or MPLW515L mutations or the TEL-JAK2 fusion gene (expressing a constitutively activated JAK2) with IC₅₀ of 11-120 nM, but has only minimal cytotoxicity against most other hematopoietic cell lines that have no constitutively activated JAK2.</p> <p>Ilginatinib hydrochloride (0.5 μM) preferentially suppresses colony-forming unit/granulocyte/macrophage</p>

体内研究(In Vivo)	<p>Ilginatinib hydrochloride (NS-018 hydrochloride) (12.5, 25, 50, 100 mg/kg, p.o.) potently prolongs the survival of mice and reduces splenomegaly in a mouse Ba/F3-JAK2V617F disease model.</p> <p>Ilginatinib hydrochloride (25, 50 mg/kg, p.o.) significantly reduces leukocytosis, hepatosplenomegaly and extramedullary hematopoiesis, improves nutritional status, and prolongs survival in JAK2V617F transgenic mice.</p> <p>has not independently confirmed the accuracy of these methods. They are for reference only.</p>
包装储存	4°C, sealed storage, away from moisture In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶解度数据	In Vitro: DMSO : ≥ 35 mg/mL (82.18 mM)H ₂ O : 2 mg/mL (4.70 mM; Need ultrasonic)